Oxford Gene Technology Launches CytoSure Products for the Cytogenetics Research Community

Oxford Gene Technology (OGT) announces the launch of two array CGH (aCGH) products designed exclusively for the cytogenetics research community. Branded under the family name CytoSure™, Syndrome Plus and Chromosome X exon specific arrays will debut at the European Cytogenetics Association conference in Istanbul, 7th-10th July, 2007.

CytoSure Syndrome Plus is a 105,000 feature array covering the whole genome, and includes probes designed to 85 constitutional syndromes - including Cri du Chat, di Georges and Prader-Willi – and other clinically relevant regions.

CytoSure ChrX array, a 44,000 feature array, has been developed in collaboration with Dr Philippos Patsalis, Chief Executive and Medical Director at the Cyprus Institute of Neurology and Genetics in Nicosia, Cyprus. This unique design provides comprehensive coverage of all relevant clinical areas across the X chromosome at high resolution.

CytoSure arrays will be supplied with complimentary visualisation software incorporating Copy Number Variation, gene and exon annotation to ease data interpretation and build confidence.

Dr Mike Evans, CEO of Oxford Gene Technology said: “We are very excited at OGT to be launching the CytoSure family – these are the only oligonucleotide arrays designed exclusively for the cytogenetics community and will enable cytogeneticists to achieve accurate, high resolution analysis of chromosome copy number and structural changes.”